

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-34. (Canceled)

35. (New) An isolated *Helicobacter pylori*-specific peptide comprising a minimum sequence of eight consecutive amino acids deduced from SEQ ID NO:36, wherein said sequence comprises a T-cell or B-cell epitope of *Helicobacter pylori*.

36. (New) An isolated *Helicobacter pylori*-specific polynucleotide comprising a nucleic acid sequence encoding the peptide of claim 35.

37. (New) An expression vector comprising the polynucleotide of claim 36 operably linked to regulatory regions that facilitate expression of said polynucleotide.

38. (New) A host cell transformed with the polynucleotide of claim 36.

39. (New) A host cell comprising the expression vector of claim 37.

40. (New) The peptide of claim 35, wherein said peptide is recombinantly expressed.

41. (New) A pharmaceutical composition comprising the peptide according to claim 35 and a pharmaceutically acceptable carrier.

42. (New) A pharmaceutical composition, which comprises the isolated polynucleotide according to claim 36 and a pharmaceutically acceptable carrier.

43. (New) A diagnostic agent comprising the peptide according to claim 35.

44. (New) An isolated *Helicobacter pylori*-specific peptide comprising a minimum sequence of eight consecutive amino acids from SEQ ID NO:37, wherein said sequence comprises a T-cell or B-cell epitope of *Helicobacter pylori*.

45. (New) The peptide of claim 35 wherein the minimum sequence is ten consecutive amino acids deduced from SEQ ID NO:36.

46. (New) The pharmaceutical composition of claim 41, which additionally comprises an adjuvant.
47. (New) A pharmaceutical composition comprising the isolated polynucleotide of claim 36 and a pharmaceutically acceptable carrier.
48. (New) A pharmaceutical composition comprising the peptide of claim 40 and a pharmaceutically acceptable carrier.
49. (New) The pharmaceutical composition of claim 42, which additionally comprises an adjuvant.
50. (New) The pharmaceutical composition of claim 47, which additionally comprises an adjuvant.
51. (New) A diagnostic agent comprising the peptide according to claim 40.
52. (New) A diagnostic agent comprising the polynucleotide of claim 36.
53. (New) The pharmaceutical composition of claim 42, wherein said polynucleotide is operably linked to regulatory regions that facilitate expression of said isolated nucleic acid.
54. (New) The pharmaceutical composition of claim 47, wherein said polynucleotide is operably linked to regulatory regions that facilitate expression of said isolated nucleic acid.
55. (New) A polynucleotide comprising an isolated nucleic acid sequence encoding the peptide of claim 44.
56. (New) A pharmaceutical composition comprising the peptide according to claim 44 and a pharmaceutically acceptable carrier.
57. (New) A diagnostic agent comprising a peptide according to claim 44.
58. (New) The peptide of claim 44 wherein the minimum sequence is ten consecutive amino acids from SEQ ID NO:37.
59. (New) The peptide of claim 44, wherein said peptide is recombinantly expressed.